Literature DB >> 2995747

Protection from cerebral ischemia by U-50,488E, a specific kappa opioid analgesic agent.

A H Tang.   

Abstract

U-50,488E is a novel analgesic agent with a specific agonist property on the kappa opioid receptor. It is found to protect against the lethal effect of temporary bilateral carotid occlusion (BCO) in Mongolian gerbils and rats of the Fischer strain. Pretreatment with U-50,488E in gerbils before 7 min of BCO reduced the development of behavioral hyperactivity and preserved the hippocampal neurons from ischemic death. This protective effect of U-50,488E resided predominantly in the levo-enantiomer which is also more potent as a kappa analgesic. Two other kappa opioid analgesics, ethylketocyclazocine and bremazocine, shared the effects of U-50,488E in the gerbils. Naloxone and dynorphin 1-13, on the other hand, were without protective effects in the same ischemic model. The ischemic protective effects of U-50,488E may involve the kappa opioid receptor.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2995747     DOI: 10.1016/0024-3205(85)90178-x

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  4 in total

1.  Neuroprotective actions of GR89696, a highly potent and selective kappa-opioid receptor agonist.

Authors:  P J Birch; H Rogers; A G Hayes; N J Hayward; M B Tyers; D I Scopes; A Naylor; D B Judd
Journal:  Br J Pharmacol       Date:  1991-07       Impact factor: 8.739

Review 2.  Mechanisms of ischemic brain damage.

Authors:  Anish Bhardwaj; Nabil J Alkayed; Jeffrey R Kirsch; Patricia D Hurn
Journal:  Curr Cardiol Rep       Date:  2003-03       Impact factor: 2.931

3.  Kappa Opioid Receptor Agonist and Brain Ischemia.

Authors:  Chen Chunhua; Xi Chunhua; Sugita Megumi; Liu Renyu
Journal:  Transl Perioper Pain Med       Date:  2014

Review 4.  Pre-clinical to Clinical Translational Failures and Current Status of Clinical Trials in Stroke Therapy: A Brief Review.

Authors:  Neha Dhir; Bikash Medhi; Ajay Prakash; Manoj Kumar Goyal; Manish Modi; Sandeep Mohindra
Journal:  Curr Neuropharmacol       Date:  2020       Impact factor: 7.363

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.